Lv1
40 积分 2021-03-28 加入
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
11小时前
待确认
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
3个月前
已完结
evaluación de desempeño del servicio de dosificación de precisión para vancomicina en un hospital pediátrico de nivel terciario
3个月前
已关闭
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
3个月前
已关闭
Flare Phenomenon After 177Lu-DOTA-IBA Therapy in Bone Metastases of Lung Cancer
5个月前
已完结
Treatment of Bone Metastases of Breast Cancer With 177Lu-DOTA-IBA
5个月前
已完结
68Ga-DOTA-IBA Uptake in Breast cancer
5个月前
已完结
Increased Uptake of 68Ga-DOTA-IBA in Lymph Node Metastases of Prostate Cancer
5个月前
已完结
Response Evaluation Using 68Ga-DOTA-IBA in a Case of Metastatic Prostate Cancer
5个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
6个月前
已完结
皖公网安备34019202002308
